Kymera Therapeutics (NASDAQ:KYMR) Releases Quarterly Earnings Results, Beats Estimates By $0.10 EPS

Kymera Therapeutics (NASDAQ:KYMR) released its quarterly earnings data on Wednesday. The company reported ($0.58) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.10, Briefing.com reports. The business had revenue of $25.60 million for the quarter, compared to analyst estimates of $12.55 million. Kymera Therapeutics had a negative return on equity of 31.92% and a negative net margin of 194.67%. The company’s revenue was up 55.2% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.67) EPS.

Kymera Therapeutics Price Performance

Shares of Kymera Therapeutics stock traded down $0.57 during trading on Friday, hitting $41.44. The stock had a trading volume of 296,304 shares, compared to its average volume of 668,746. The firm has a market cap of $2.54 billion, a P/E ratio of -16.51 and a beta of 2.22. The business has a fifty day moving average of $37.09 and a two-hundred day moving average of $37.05. Kymera Therapeutics has a fifty-two week low of $9.60 and a fifty-two week high of $48.70.

Insider Activity

In other news, Director Joanna Horobin sold 8,500 shares of the company’s stock in a transaction on Friday, June 7th. The stock was sold at an average price of $32.99, for a total transaction of $280,415.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, Director Bruce Booth sold 16,740 shares of the stock in a transaction dated Wednesday, June 12th. The stock was sold at an average price of $35.45, for a total value of $593,433.00. Following the completion of the sale, the director now directly owns 803,792 shares of the company’s stock, valued at approximately $28,494,426.40. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Joanna Horobin sold 8,500 shares of the stock in a transaction dated Friday, June 7th. The stock was sold at an average price of $32.99, for a total value of $280,415.00. The disclosure for this sale can be found here. Insiders sold a total of 502,345 shares of company stock valued at $19,279,932 over the last three months. Insiders own 15.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 target price on shares of Kymera Therapeutics in a research report on Monday, June 17th. Oppenheimer reaffirmed an “outperform” rating and issued a $52.00 target price on shares of Kymera Therapeutics in a research report on Wednesday, July 10th. Finally, B. Riley upped their target price on Kymera Therapeutics from $31.00 to $36.00 and gave the company a “neutral” rating in a research report on Tuesday, July 9th. Six analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, Kymera Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $42.60.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.